Drug Trial Radar · NCT00083824
Estrogen, HDL, and Coronary Heart Disease in Women
Last checked: Nov 20, 2026Latest source record: Apr 21, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
309
Actual
Start
Mar 2004
Primary completion
Feb 2007
Study completion Feb 2007
Sponsor
- Lead sponsor
- Tufts UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- First posted
- Jun 4, 2004
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Health services research
- Who can join
- Female only, from 55 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To clarify the effects of estrogen, with or without progestin, on high density lipoprotein (HDL) in postmenopausal women.
Conditions
- Cardiovascular Diseases
- Coronary Disease
- Heart Diseases
- Coronary Arteriosclerosis
Interventions
Estrogens, Conjugated (USP)Drug
0.625 mg/day QID for 3 years
Medroxyprogesterone 17-AcetateDrug
2.5 mg/day QID for 3 years
PlaceboDrug
2 pills/day QID for 3 years
Primary outcomes
What the sponsor says the trial is designed to measure.
- HDL subpopulation distribution and compositionTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
HNRCA at Tufts University
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.